Montagna Symposium 2008: The Biologic Basis of Psoriasis  by Blauvelt, Andrew et al.
meeting report
© 2009 The Society for Investigative Dermatology www.jidonline.org 259
1Department of Dermatology, Oregon Health & Science University, Portland, Oregon, USA; 2Department of Molecular Microbiology & Immunology, Oregon 
Health & Science University, Oregon, USA; 3Dermatology Service, Veterans Affairs Medical Center, Portland, Oregon, USA; 4Department of Anatomy and Cell 
Biology, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA and 5Division of Human Genetics, Departments of Genetics, Pediatrics and 
Medicine, Washington University, St. Louis, Missouri, USA
Correspondence: Dr Andrew Blauvelt, Department of Dermatology, Oregon Health & Science University, 3710 SW US Veterans Hospital Road, Mail Code 
R&D 55, Portland, Oregon 97239, USA. E-mail: blauvean@ohsu.edu
major players in psoriasis pathogenesis. 
This talk provided the perfect backdrop 
for the meeting, because many talks in 
subsequent sessions required a basic 
understanding of the fundamental dis-
coveries with regard to the IL-23/Th17 
inflammatory pathway.
During the first full day of the meeting, 
geneticists from around the world took 
center stage. J.T. Elder and Anne Bowcock 
presented soon-to-be-published results 
from a genome-wide association study 
of psoriasis supported by the Genetic 
Association Information Network. This 
revealed strong support for the association 
of at least seven genetic loci with psoriasis, 
including HLA-C, IL-12/23p40, IL-23p19, 
IL-23R, IL-4/13, TNFAIP1, and TNFAIP3. 
Eniko Sonkoly then described altered 
expression of microRNAs in psoriasis. 
MicroRNAs are small molecules (approx-
imately 20 bases) that play an important 
role in translational regulation. Recent 
evidence from Dr. Sonkoly and her group, 
as well as Cailin Joyce in Anne Bowcock’s 
group, indicates that the expression of 
several microRNAs is altered in psoriasis, 
including miR-31, miR-21, miR-133a/b, 
and miR-203. Joost Schalkwijk described 
copy-number alterations in psoriasis, 
including those within the β-defensin 
cluster of genes, and the late cornified 
envelope cluster of genes within the epi-
dermal differentiation complex. Christina 
de Guzman Strong described genomic 
analyses for identifying genetic regions 
important for normal skin barrier function. 
Frank Nestle outlined a gene-to-clinic 
example that involved IL-23 and included 
More than 100 physicians, scientists, resi-
dents, students, and pharmaceutical com-
pany representatives attended the 2008 
Montagna Symposium, The Biologic 
Basis of Psoriasis,* including most of the 
world’s leading research experts working 
on psoriasis. The program was divided 
into four major sections: (i) the genetics of 
psoriasis, (ii) mouse models of psoriasis, 
(iii) T cell and keratinocyte biology, and 
(iv) translational/human studies. In addi-
tion to major talks by invited speakers, 
the meeting included short talks selected 
from meritorious abstracts, ample discus-
sion time after each talk, and interactive 
breakout sessions with small groups that 
focused on specific research questions 
and future research priorities. Because 
of the intimate lodge setting and the rela-
tively small size of the meeting, attend-
ees had numerous opportunities to inter-
act during the scientific sessions as well 
as during both planned and unplanned 
social events.
The meeting began with a keynote 
address by Rene de Waal Malefyt, 
who has been an integral member of a 
research team that performed pioneer-
ing studies on the IL-23/T helper (Th)17 
inflammatory pathway. Dr. de Waal 
Malefyt described the rationale behind 
the science that led to the discovery of 
IL-23, delineated the differentiation path-
ways for both human and murine Th17 
cells, explored the role of IL-23–driven 
Th17 responses versus IL-12–driven Th1 
responses in well-defined mouse models 
of autoimmunity, and summarized the 
data implicating IL-23 and Th17 cells as 
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studies on polymorphisms encoding for 
IL-12/23p40, blocking this protein in a 
xenograft model of psoriasis and summa-
rizing clinical data in patients treated with 
ustekinumab, a monoclonal antibody 
directed against IL-12/23p40. Last, Julie 
Segre presented ongoing groundbreaking 
work exploring the genetics of microbial 
flora present within normal skin, com-
monly referred to as the skin microbiome. 
Hundreds of bacterial species are present 
within normal skin, far more than can be 
simply cultured, and species appear to 
vary widely in different body parts and 
when sampled in different ways, such as 
by swabbing or biopsying skin.
The second scientific session cen-
tered on mouse models of psoriasis. 
John DiGiovanni and Shigetoshi Sano 
described transgenic mice that over-
expressed Stat3 within basal keratino-
cytes. These mice display many his-
tologic and immunologic features of 
psoriasis, including the development of 
psoriasis-like lesions at sites of trauma. 
Xiao-Jing Wang summarized ongoing 
work using transgenic mice that overex-
press TGF-β1 within basal keratinocytes. 
Deleting T cells in these mice leads to 
a delay in, but not complete protec-
tion from, developing skin disease. The 
final portion of this session, introduced 
by Brian Nickoloff, included small but 
spirited group discussions on the rela-
tive merits and drawbacks of the many 
mouse models of psoriasis, as well as a 
discussion on the ways in which these 
models could be evaluated and scored 
in a standardized manner.
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The third scientific session began 
with talks focused on T cell biology. 
Rachael Clark discussed the pheno-
type and cytokine expression profile 
of populations of cutaneous T cells. 
Subsequent talks by Kevin Cooper and 
Hideaki Sugiyama centered on the role 
of regulatory T cells in the pathogenesis 
of psoriasis, including a delineation of 
how IL-6 contributes to dysfunction 
of these cells within psoriatic tissue. 
Andrew Blauvelt presented unpub-
lished data showing high numbers of 
CCR6+ Th17 cells in the blood of pso-
riatics (compared with that of healthy 
individuals), with decreased numbers 
of the cells following infliximab therapy. 
Allen Bruce presented interesting data 
on how cytokines derived from both Th1 
and Th17 cells acted in syn ergistic ways 
to promote inflammation in psoriasis, 
in contrast to recent papers suggesting 
that Th1 responses down regulated Th17 
responses and vice versa.
The second half of the third scien-
tific session centered on keratinocyte 
biology. It began with Wenjun Ouyang 
describing how IL-22 and other IL-20 
cytokine family members stimulate 
proliferation and production of antimi-
crobial peptides by keratinocytes. This 
theme was continued with a presenta-
tion by Andrew Johnston, who showed 
that EGFR signaling and IL-1 also con-
tributed significantly to antimicrobial 
defenses in keratinocytes. Yuangang 
Liu showed how the chemokine CCL20 
differentially regulated the expression 
of Trim32 and Piasy, two molecules 
involved in keratinocyte growth signal-
ing pathways. Last, Ewout Baerveldt 
reported on how neuropeptides affect 
keratinocyte biology.
The translational/human studies ses-
sion began with James Krueger describing 
numerous published and unpublished 
studies on cytokine mRNA and protein 
expression in skin samples obtained 
from individuals with psoriasis, atopic 
dermatitis, and healthy skin. Importantly, 
Dr. Krueger’s work has been critical in 
the understanding of both Th17 and Th1 
inflammatory networks in psoriasis and 
has resulted in the ability to develop and 
test comprehensive global hypotheses 
on the cellular immunology of psoriasis. 
Kristina Callis Duffin, who works with 
the Utah Psoriasis Initiative, described 
genotype–phenotype studies with an 
emphasis on particular genetic changes 
that correlated with how psoriasis was 
affected by pregnancy and smoking. The 
formal meeting ended with a presenta-
tion by Joel Gelfand, who reported on 
data linking moderate to severe psoriasis 
with increased risk of myocardial infarc-
tion, stroke, and mortality.
2008 SiD eugene m. Farber travel Awards 
for Young investigators
As in the past, nine young investiga-
tors were able to attend the Montagna 
Symposium thanks to a generous donation 
from the Eugene M. Farber family through 
the Society for Investigative Dermatology:
Ewout Baerveldt, MD
Departments of Dermatology and Immunology,  
Erasmus MC, University Medical Center, 
Rotterdam, The Netherlands
Anne-Marie Broome, PhD, MBA
Departments of Biomedical Engineering and  
Radiology, Case Western Reserve University, 
Cleveland, OH
Allen Bruce, MD, PhD
Department of Dermatology, University of 
Michigan, Ann Arbor, MI
Cristina de Guzman Strong, PhD
Epithelial Biology Section/Genetics and Molecular 
Biology Branch, National Human Genome 
Research Institute, National Institutes of Health, 
Bethesda, MD
Ingrid Freeny, MD
Department of Dermatology, University of Utah, 
Salt Lake City, UT
Emma Guttman, MD, PhD
Department of Dermatology, Cornell University, 
and Laboratory of Investigative Dermatology, 
Rockefeller University, NY, NY
Reto Huggenberger, MSC
Department of Pharmaceutical Sciences,  
Swiss Federal Institute of Technology,  
Zurich, Switzerland
Andrew Johnston, PhD
Department of Dermatology, University of 
Michigan, Ann Arbor, MI
Cailin Joyce, BS
Department of Genetics, Washington University in 
St. Louis, St. Louis, MO
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*The 2008 Montagna Symposium, “The 
Biologic Basis of Psoriasis,” was held at the 
Salishan Resort, Gleneden Beach, Oregon, 
USA, 2–6 October 2008. 
Information about content and support of past 
Symposia and the next Montagna Symposium 
on the Biology of Skin can be found at http://
www.montagnasymposium.org.
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